

My patient
and their partner
need answers



Targeted, efficient **STI*** screening and diagnostics

*Sexually-transmitted infections

When certain diagnostic methods may be less sensitive, **how can you help ensure rapid, accurate detection?**

>1 billion

STIs are acquired
every day
worldwide.¹

156 million

Estimated infections
of *Trichomonas*
vaginalis per year
worldwide.²

>75%

of women experience
at least one episode
of vaginitis in their
lifetime.³

STIs impose a substantial strain on national health systems. Because many STIs share common symptoms with patients often appearing asymptomatic altogether, they can be challenging to differentiate. Certain diagnostic methods such as wet preparation microscopy and antigen testing may be less sensitive in detecting and differentiating different STIs.^{4,5}

When left undetected, STIs can lead to severe patient complications including infertility, brain damage and possibly death.⁶

What if you could help ensure rapid STI detection by...



Simultaneously
screening multiple
STIs from a single
patient sample?



Eliminating
the need for a
confirmatory test?



Providing **same-day**
results for rapid
clinical decisions?



Performing
diagnostic tests with
high sensitivity
and **specificity?**

Harnessing the reliability of NAATs, STI screening and diagnosis on the **BD MAX™ System** combines innovation with rapid, accurate molecular testing. With our STI portfolio, your lab can benefit from:

- **Direct, simultaneous detection** of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* from a single patient sample.
- Dual targets for detection of chlamydia and gonorrhoeae, **eliminating the need for a confirmatory test**⁷
- Only **one vaginal swab specimen needed** to run BD CTGCTV2 or BD CTGC2 and BD Vaginal Panel
- The first semi-quantitative assay that **holistically observes the microbiome** to diagnose bacterial vaginosis

The right treatment starts with the right test

NEW

BD CTGCTV2 for BD MAX™ System

- *Chlamydia trachomatis*
- *Neisseria gonorrhoeae*
- *Trichomonas vaginalis*

Cat: 443906

NEW

BD CTGC2 for BD MAX™ System

- *Chlamydia trachomatis*
- *Neisseria gonorrhoeae*

Cat: 443905

BD MAX™ Vaginal Panel

- Bacterial vaginosis
- Candidiasis
- Trichomoniasis

Cat: 443712

BD MAX™ GBS

- Group B Streptococcus

Cat: 441772

← Both symptomatic or asymptomatic men and women →

← Vaginal swab specimen (clinician collected and self-collected in a healthcare setting) →

← Endocervical swab, urine and LBC specimen →

← Symptomatic women →

← Antepartum pregnant women →

← Vaginal-rectal swab →

Chlamydia trachomatis, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* can now be detected for both symptomatic and asymptomatic men and women with the **newly launched BD CTGCTV2 assay** on the BD MAX™ System.

You can also test for *Mycoplasma genitalium* on the BD MAX™ System through an open system assay and extraction kit. For further information, **please contact your BD representative.**

Rapid, targeted STI testing on BD molecular platforms

Whatever your lab's testing throughput, the innovative BD molecular platforms respond to your workflow needs with efficiency and ease of use. An automated workflow **reduces manual tasks** to achieve rapid, reliable results and facilitates off-hour testing, helping to **offset molecular testing costs.****^{8,9}

The **BD MAX™ System**, a fully automated, molecular platform providing rapid results for low to mid-volume testing needs



The **BD COR™ System**, a fully automated platform for high-throughput screening of STIs



Discover our full assay portfolio and the BD MAX™ System



advancing-diagnostics.eu



advancingdiagnostics@bd.com

¹. European Centre for Disease Prevention and Control. Developing a national strategy for prevention and control of sexually transmitted infections. Available at: <https://www.ecdc.europa.eu/sites/default/files/documents/strategies-to-control-STIs.pdf>. ². Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections: National Strategic Plan for the United States, 2021-2025. Accessed January 2022, at <https://www.hhs.gov/sites/default/files/STI-National-Strategic-Plan-2021-2025.pdf>. ³. Workowski KA and Bolan GA. MMWR. Recomm Rep. 2021;64(RR-03):1-137. ⁴. Gaydos C, Klausner J, Pai N, Kelly H, Coltar C, and Peeling R. Rapid and point-of-care tests for the diagnosis of *Trichomonas vaginalis* in women and men. Sex Transm Infect. 2017; 93(54):S31-S35. ⁵. Guy R, Causer L, Klausner J, Unemo M, Toskin I, Azzini A and Peeling R. Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect. 2017; 93(54): S16-S21. ⁶. National Institute of Allergy and Infectious Diseases. Sexually Transmitted Diseases (STDs) Diagnosis. 2015. Available at: <https://www.niaid.nih.gov/diseases-conditions/sexually-transmitted-diseases>. Accessed January 2022. ⁷. Reference: Guidance for the detection of gonorrhoea in England: updated guidance 2021 Available at: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972388/Guidance_for_the_detection_of_gonorrhoea_in_England_2021.pdf. Accessed on January 2022. ⁸. Mortensen JE, et al. Comparison of time-motion analysis of conventional stool culture and the BD MAX Enteric Bacterial Panel (EBP). BMC Clin Pathol. 2015;15:9. ⁹. Hirvonen JJ, et al. Comparison of BD Max Cdiff and GenomEra C. difficile molecular assays for detection of toxigenic *Clostridium difficile* from stools in conventional sample containers and in FecalSwabs. Eur J Clin Microbiol Infect Dis. 2015;34(5):1005-1009.

** When compared to culture or immunochromatographic antigen (IA)

The BD MAX™ System, BD MAX™ Vaginal Panel and BD MAX™ GBS assay are in-vitro diagnostic medical devices bearing a CE-mark. The BD CTGCTV2 & BD CTGC2 for BD MAX™ System are in-vitro diagnostic medical devices bearing a CE-mark, and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797). **BD, the BD Logo, MAX are trademarks of Becton, Dickinson and Company or its affiliates. BD-52409 © 2022 BD. All rights reserved.**